



**Government of the District of Columbia  
Department of Health**



**899 NORTH CAPITOL ST. NE – 2<sup>ND</sup> FLR.  
WASHINGTON, DC 20002**

**April 6, 2017**

**9:30am- 11:30 am**

**OPEN SESSION AGENDA**

**Board of Pharmacy Mission Statement:**

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”



## Open Session Agenda

### Quorum:

<b>Introduction:</b>		
<b>0406-O-01</b>	<b><u>Approval of the Open Session Meeting Minutes</u></b> February 2, 2017	
<b><u>Consent Agenda</u></b>	<b>None</b>	
<b><u>Executive Director Report</u></b>	<b><u>Licensing Report</u></b>  <b>Statistics</b> <b>Pharmacist and Technician Renewal Update</b>	
<b><u>Assistant General Counsel Report</u></b>		Carla Williams
<b>0406-O-02</b>	<b>Pharmaceutical Detailing Emergency Legislation</b>  (a) B21-0989 Engrossment (b) PR21-1097 Introduction (c) B21-0988 Enrollment	
<b>0406-O-03</b>	<b>LGBTQ regulations for Pharmacists, Pharmaceutical Detailers, and Pharmacy Technicians</b>  (a) Notice of Proposed Rulemaking (Public comment ends on April 15, 2017)	
<b><u>Subcommittee Report</u></b>		Mr. Alan Friedman
	<b><u>Legislative and Regulatory</u></b>	
<b>0406-O-04 FYI</b>	<b>Notice of Proposed Rulemaking –Collaborative Practice Agreement Regulations</b>  During the February Board meeting the moved to approve the revised collaborative practice regulations as presented and to move forward with publication for consideration.	
<b>0406-O-05</b>	<b><u>Communications Subcommittee Report</u></b>	Dr. Daphne Bernard
<b>0406-O-06</b>	<b><u>DOH Pharmacy Intern Presentation</u></b> Pharmacy News	

<p><b>NABP E-Newsletter</b></p>	<p><b>March 15, 2017</b></p> <p><u><a href="#">US and EU Regulators Agree to Recognize Each Other’s Inspections of Manufacturing Sites for Human Medicines</a></u></p> <p><u><a href="#">Maryland Governor Declares State of Emergency to Combat Opioid and Heroin Epidemic</a></u></p> <p><u><a href="#">Gabapentin Abuse and Misuse Is Increasing Throughout Ohio</a></u></p> <p><u><a href="#">AWARxE Website Content Is Moving to the NABP Website</a></u></p> <p><u><a href="#">Websites Offering Health Care Services With Limited Clinical Oversight Worry Regulators in England, Spark Investigation</a></u></p> <p><b>March 22, 2017</b></p> <p><u><a href="#">Colorado Manufacturers and Distributors of Unapproved Drugs and Dietary Supplements Ordered to Cease Operations</a></u></p> <p><u><a href="#">New York City Launches Initiative to Reduce Opioid Overdose Deaths</a></u></p> <p><u><a href="#">Fluoroquinolone Safety Labeling Updates Presented in Latest FDA Webinar</a></u></p> <p><u><a href="#">New FDA Drug Info Rounds Training Video Addresses the Combat Methamphetamine Epidemic Act</a></u></p> <p><u><a href="#">FDA Podcast Discusses the Agency’s Priorities in 2017</a></u></p>	
<p><b><u>Matters for Board Consideration</u></b></p>	<p><b>None</b></p>	
<p><b>Comments from the Public</b></p>		
<p><b>Motion to Adjourn the Open Session</b></p>	<p>Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4);</p>	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

**Open Session Meeting Adjourned at \_\_:\_\_**